128
128
362
362
377
377
251
251
2020
2017
University (1.1K)
1 - 10 of 1,118
Sort by
Opportunity
IDFBX2:9421Post Date2020-06-17
Human-derived induced pluripotent stem cells (hiPSCs) are revolutionizing the drug discovery and development process used by pharmaceutical companies to identify lead drug candidates. The iPSC technology facilitates the development of diverse range of cellular models to test a wide spectrum of drug susceptibilities and resistances, thereby offering a "clinical trial in a dish". Despite the prospects of iPSCs in drug discovery, there are still several unmet challenges that slows down progr…
Opportunity
IDFBX2:9420Post Date2020-06-17
A demand for a technology that can accurately predict cardiotoxicity during drug discovery is high. Usage of human induced pluripotent stem cell (iPSC) to derive cardiac tissue is a powerful tool to conduct research on predictive toxicology. GE lifescience's Cytiva, and iCell Cardiomyocytes from Cellular Dynamics International are two great examples that had been successfully marketed for usage of iPSC in cardiotoxicology. The newly developed technology brings further advancement to this e…
Opportunity
IDFBX2:9381Post Date2020-06-09
U-M researchers have developed a suite of hygienic shields or breath shields for use during ophthalmologic exams in order to reduce eye care professionals' risk of exposure to pathogens in breath droplets and other secretions. All designs are available for download for easy and rapid fabrication by anyone with access to a CNC machine. This specific listing is for a hygienic shield or breath shield custom designed to fit Keeler ophthalmoscope lamps. The shield is designed to protect…
Opportunity
Track Code9120Post Date2020-06-06TypeAvailable Technology
This technology allows for co-differentiation of intestinal vascular endothelial cells in a human intestinal organoid culture. Although organoid culture has been previously established, these cultured tissues do not possess all components found in the body. This system allows for better replication of the in vivo intestine in an in vitro system.
Opportunity
Track Code9119Post Date2020-06-06TypeAvailable Technology
This technology uses a targeted approach to treat diabetic foot ulcers with a topical nanoparticle composite containing anti-inflammatories, mitigating side effects seen in systemic treatment. This method has been shown to reduce wound healing time in diabetic mouse model by 30%.
Opportunity
Track Code9300Post Date2020-06-06TypeAvailable Technology
BackgroundWith the current device architectures, slower-speed electronics and complex optical electrical-optical (O/E/O) conversion are required to perform computation. Despite the development of several all-optical logic gate architectures, the lack of a practical optical information storage technology makes sequential binary operations using these devices very difficult and thus severely limits the computational scaling capability. Although a variety of technique…
Opportunity
Track Code9118Post Date2020-06-06TypeAvailable Technology
This technology consists of an improved method for rapidly diagnosing and staging cancer. It utilizes a sequence-based method featuring key innovations that improve both wet-lab and computational time to diagnosis. This allows for rapid decisions on a treatment plan.
Opportunity
Track Code9114Post Date2020-06-06TypeAvailable Technology
This technology identifies novel enzymes capable of degrading xanthan gum, a common food additive. Adapting these enzymes to native gut bacterial will aid individuals in digesting xanthan gum and prevent intestinal distress.
Opportunity
Track Code9117Post Date2020-06-06TypeAvailable Technology
Currently, there is no effective therapeutic to treat or prevent flavivirus infection on a broad scale. Flavivirus is responsible for several mosquito borne diseases including dengue, Zika, and West Nile. This technology consists of an antibody against a common structure in flavivirus responsible for all three diseases. Targeting this structure provides a novel therapeutic to treat these diseases.
Opportunity
Track Code9098Post Date2020-06-06TypeAvailable Technology
This technology describes a novel source of Type I CRISPR machinery. This system is derived from a different bacterium than current systems. Studies show that it is both smaller and more stream line to use, possesses high editing efficiency, and is easy to purify and prepare. These attributes make this an attractive system for genome editing of mammalian cells.